RECRUITING

Mobile Regulation of Craving Training (mROC-T) to Improve Dietary Intake in Rural Adolescent Girls

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test if a regulation of craving training intervention in the form of a mobile phone app can increase fruit and vegetable intake in adolescent girls ages 14-18 years of age. The main questions it aims to answer are: 1. What is the effect of a mobile app version of the regulation of craving training intervention on healthy eating index scores over one year? 2. What is the effect of a mobile app version of the regulation of craving training intervention on body mass index, waist circumference, and blood glucose over one year? Researchers will compare the active regulation of craving training arm to a control fun food fact arm to see if the regulation of craving training improves HEI scores, BMI, and blood glucose over a year. Participants will be asked to play the regulation of craving training mobile app twice a week for a year.

Official Title

Mobile Regulation of Craving Training (mROC-T) to Improve Dietary Intake in Rural Adolescent Girls

Quick Facts

Study Start:2025-02-01
Study Completion:2026-02-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06723028

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Biologically female
  2. * Female gender
  3. * Between the ages of 15y and 18y
  1. * Biologically male
  2. * Self-identify as male
  3. * BMI percentile (for age and sex) \< 5th%
  4. * Diagnosis from a medical profession of any of the following conditions, syndromes, diseases that may affect growth, glucose metabolism, blood clotting, cognitive development\*:
  5. * Any form of or history of cancer
  6. * Any form of diabetes (type I, II, insipidus)
  7. * Precocious puberty
  8. * Crohn's disease
  9. * Congenital heart defect
  10. * Cystic fibrosis
  11. * Cerebral palsy
  12. * Anorexia nervosa
  13. * Bulimia nervosa
  14. * Active infection
  15. * Fever
  16. * Hemophilia
  17. * Hydrocephalus
  18. * intestinal atresia
  19. * Jeune syndrome
  20. * Klippel-Trénaunay syndrome
  21. * Legg-Calvé-Perthes
  22. * Long QT syndrome
  23. * Muenke syndrome
  24. * Myelomeningocele
  25. * Necrotizing Enterocolitis
  26. * Neutropenia
  27. * Non-alcholoic fatty liver diease
  28. * Pfeiffer Syndrome
  29. * Saethre-Chotzen syndrome
  30. * Shwachman-Diamond syndrome
  31. * Spinal muscular atrophy
  32. * Sturge-Weber syndrome
  33. * Ulcerative Colitis
  34. * von Willebrand disease
  35. * Pancreatitis
  36. * Hurler syndrome
  37. * Niemann-Pick disease
  38. * Tay-Sachs disease
  39. * Gaucher disease
  40. * Krabbe disease
  41. * Zellweger syndrome
  42. * Wilson disease
  43. * Brachial Plexus Palsy
  44. * Brain Abscess or Spinal Abscess
  45. * Coarctation of the Aorta
  46. * Aortic stenosis
  47. * Ventricular septal defect
  48. * Patent ductus arteriosus or mitral valve abnormalities
  49. * Congenital Adrenal Hyperplasia
  50. * Craniofacial Microsomia
  51. * Duchenne Muscular Dystrophy
  52. * Dyskeratosis Congenita
  53. * Galactosemia
  54. * Maple syrup urine disease
  55. * Phenylketonuria
  56. * Turner syndrome
  57. * Prader-Wili disease
  58. * History of polycystic ovary syndrome
  59. * History of thyroid disease (either hyper or hypo)
  60. * History of adrenal disease (including Cushing's syndrome, Addison's disease)
  61. * Use of medications related to metabolism/weight such as insulin, corticosteroids, growth hormone, sulfonylurea, thiazolidinediones, beta blockers, calcium channel blockers, bupropion, reboxetine, molindone, clozapine, olanzapine, topiramate, zonisamide, valproate, carbamazepine, lithium, hypolipidemic drugs, highly-active antiretroviral therapies

Contacts and Locations

Study Contact

Grace Shearrer, PhD
CONTACT
3033326334
gshearre@uwyo.edu

Principal Investigator

Grace Shearrer, PhD
PRINCIPAL_INVESTIGATOR
University of Wyoming

Study Locations (Sites)

University of Wyoming
Laramie, Wyoming, 80270
United States

Collaborators and Investigators

Sponsor: University of Wyoming

  • Grace Shearrer, PhD, PRINCIPAL_INVESTIGATOR, University of Wyoming

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-01
Study Completion Date2026-02-01

Study Record Updates

Study Start Date2025-02-01
Study Completion Date2026-02-01

Terms related to this study

Keywords Provided by Researchers

  • mobile app
  • cognitive behavioral therapy
  • fruit and vegetable intake
  • type 2 diabetes prevention
  • rural
  • adolescents

Additional Relevant MeSH Terms

  • Obesity and Type 2 Diabetes
  • Diet Modification